BACKGROUND: The combination of statin therapy and PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition markedly lowers low-density lipoprotein cholesterol (LDL-C) and reduces cardiovascular event rates. Whether residual inflammatory risk as measured by ontreatment high sensitivity C-reactive protein (hsCRP) remains an important clinical issue in such patients is uncertain.
P
atients with residual inflammatory risk have high rates of recurrent cardiovascular events in association with persistently elevated levels of highsensitivity C-reactive protein (hsCRP) despite aggressive use of statin therapy. [1] [2] [3] [4] [5] [6] [7] Such patients, commonly defined as those taking statin therapy who have hsCRP ≥2 mg/L and low-density lipoprotein cholesterol (LDL-C) <70 mg/dL, 8 comprise nearly 30% of patients in contemporary practice and are twice as common as those with residual cholesterol risk (defined by LDL-C levels ≥70 mg/dL and hsCRP <2 mg/L). 9 Recently, the CAN-TOS study (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) demonstrated that interleukin-1 inhibition with canakinumab significantly reduces both hsCRP and cardiovascular events in stable patients with prior myocardial infarction (MI) and elevated hsCRP, 10 data providing the first potential treatment for patients with residual inflammatory risk. Indeed, the magnitude of risk reduction with canakinumab in CANTOS, despite no change in LDL-C, was virtually identical to that achieved in the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) and SPIRE (Studies of PCSK9 Inhibition and the Reduction in Vascular Events) PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor trials 11, 12 of evolocumab and bococizumab, respectively, in stable high-risk populations. Table 1 provides a brief description of design elements of these trials as well as the recently completed ODYSSEY Outcomes trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), 13 which tested the PCSK9 inhibitor alirocumab. Importantly, the absolute event rates of 5.3% and 9.1% at 1 year and 2 years on treatment with evolocumab in FOURIER inform us that many patients achieving very low LDL-C levels will continue to experience cardiovascular events. Whether residual inflammatory risk, that cardiovascular risk attributable to residual subclinical inflammation, remains an important clinical issue among statin-treated patients who additionally receive PCSK9 inhibition is unknown. We addressed this issue in the recently completed SPIRE-1 and SPIRE-2 trials.
METHODS

Data Availability
The data will not be made available to other researchers for purposes of reproducing the results. However, the methods used in the analysis are available on request.
Study Population and Procedures
The SPIRE bococizumab development program consisted of 2 parts: the 6 SPIRE lipid-lowering studies and the SPIRE-1 and SPIRE-2 event-driven cardiovascular trials. The design and primary findings of SPIRE-1 and SPIRE-2 have been previously published. 12, 14 The virtually identical designs of the 2 trials permitted them to be combined according to an integrated statistical analysis plan. In brief, patients were eligible for enrollment if they had either a prior cardiovascular event (secondary prevention cohort) or a history of diabetes mellitus, chronic kidney disease, or peripheral vascular disease with additional cardiovascular risk conditions or a history of familial hypercholesterolemia (high-risk primary prevention cohort). All patients were required to have received ≥4 weeks of stable statin therapy (atorvastatin ≥40 mg/day, rosuvastatin ≥20 mg/day, or simvastatin ≥40 mg/day) unless they could not take those doses without side effects and were thus on lower intensity statin therapy or had complete statin intolerance (eligible for SPIRE-2 only). Patients were required to have a directly measured LDL-C level of ≥70 mg/dL in SPIRE-1 and ≥100 mg/dL in SPIRE-2. Patients were also eligible according to their non-high-density lipoprotein (non-HDL) cholesterol level at entry (≥100 mg/dL for SPIRE-1 and ≥130 mg/dL for SPIRE-2). In a double-blinded fashion, patients were randomized in a 1:1 ratio to treatment with subcutaneous bococizumab 150 mg every 2 weeks or matching placebo. The SPIRE program was sponsored by Pfizer.
The study population for the current analysis comprises the subgroup of SPIRE-1 and SPIRE-2 patients who were receiving moderate-or high-intensity statin therapy, were allocated to active bococizumab, and had available baseline and 14-week hsCRP measures available for analysis
Clinical Perspective
What Is New?
• Among high-risk stable outpatients treated with moderate-or high-intensity statins and PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibition, roughly 1 in 2 had residual inflammatory risk defined by on-treatment high-sensitivity C-reactive protein (hsCRP) levels ≥2 mg/L, with roughly 1 in 3 having values >3 mg/L. • Treatment with bococizumab was associated with a 60% mean reduction in low-density lipoprotein cholesterol (LDL-C) but little change in hsCRP.
• Levels of hsCRP >3 mg/L were associated with a 60% greater risk of future cardiovascular events, corresponding to a 3.6% annual event rate (3.6 per 100 person-years) even after accounting for on-treatment LDL-C.
What Are the Clinical Implications?
• PCSK9 inhibition added to statin therapy in stable outpatients does not lower hsCRP.
• Persistent elevations of hsCRP are associated with future cardiovascular risk in these patients even after low levels of LDL-C are achieved.
• If corroborated, these data suggest that inflammation modulation may yet have a role in primary and secondary prevention of cardiovascular disease when LDL-C is controlled.
Circulation. 
End Points
The prespecified primary end point of the 2 trials was a composite of adjudicated and confirmed nonfatal MI, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death. All incident events that were components of these end points were adjudicated by a committee in which the members were unaware of treatment assignments.
Statistical Analyses
Of 13 675 patients randomized to the active treatment arm, 12 711 (93.0%) were receiving moderate-or high-intensity statin therapy, and 9738 (71.2%) also had on-treatment hsCRP (hsCRP OT ) levels available at the 14-week time point. The corresponding proportion of patients randomized to placebo, receiving statin therapy, and having follow-up biomarker levels was 9785 (71.6%). Baseline characteristics of included versus excluded patients are shown in Table I in the online-only Data Supplement. The study population was then restricted to individuals allocated to bococizumab and divided into 3 groups according to hsCRP OT level <1, 1 to 3, and >3 mg/dL comprising 30.4%, 34.8%, and 34.9% of patients, respectively. These cut points are consistent with the previously proposed Centers for Disease Control/American Heart Association classification scheme 15 and correspond to approximate tertiles of the population distribution. When cut points of <2 and ≥2 mg/dL were used, these percentages were 52.8% and 47.2%. Baseline characteristics according to the 3 primary hsCRP OT groups were summarized using percentages for categorical values and medians (interquartile ranges) for continuous variables. Trends in these characteristics across ordered hsCRP OT categories were assessed using the Cochran-Armitage trend test for differences in proportions and the Jonckheere-Terpstra test for differences in medians.
To evaluate the treatment effect of bococizumab on lipid levels and hsCRP, median on-treatment levels were determined at baseline and 14 weeks of therapy. Linear mixed-model repeated-measure analyses conditioning on the baseline value were used, with the independent value being the biomarker of interest after log transformation as deemed appropriate for nonnormal distributions. The mean percentage change and bococizumab treatment effect were estimated by fitting terms corresponding to the study drug assignment.
Percentage change in lipid levels in each hsCRP OT group among patients allocated to bococizumab was then estimated using mixed models as before, conditioning on the baseline value, and fitting a term corresponding to the hsCRP OT group.
Cox proportional hazards models were used to estimate hazard ratios (HRs) according to hsCRP OT group. Because the LDL-C-lowering effects of bococizumab emerge as early as 4 weeks after drug initiation, 12 all end points, including those occurring before 14 weeks, were used in the primary analysis. Sensitivity analyses were conducted after removing these events (Table II in the online-only Data Supplement). The 3 models presented are adjusted for (1) age and sex; (2) age, sex, traditional cardiovascular risk factors (including current smoking, diabetes mellitus, hypertension, and body mass index), plus statin intensity at enrollment (moderate or high); and (3) model 2 variables plus on-treatment LDL-C (LDL-C OT ). For each model, a test for trend across hsCRP OT categories was performed after assigning the median value to each group. All analyses were stratified by study (SPIRE-1 or SPIRE-2), region, and screening LDL-C threshold (≥70 or ≥100 mg/ dL). We also assessed for heterogeneity in treatment effects 
ORIGINAL RESEARCH ARTICLE
of bococizumab versus placebo according to hsCRP OT groups by use of an interaction term (bococizumab × hsCRP OT group).
To permit comparison to associations for on-treatment LDL-C measured at 14 weeks, the study population was additionally divided into LDL-C OT groups (approximate tertiles) using the categories of <30, 30 to 50, and >50 mg/dL, and comparable Cox models were used to estimate adjusted HRs in each of these groups. Cut points of <2 or ≥2 mg/L for hsCRP and <40 or ≥40 mg/dL for LDL-C were also used. Finally, to examine the risk association throughout the range of hsCRP OT , we plotted the relationship between hsCRP OT and cardiovascular event rates using a smoothing function to the average of estimated event rates at each hsCRP OT level based on adjusted Cox models.
RESULTS
Study Population by hsCRP OT Levels
The study population comprised 2958 (30.4%) with hsCRP OT <1 mg/L, 3385 (34.8%) with hsCRP OT 1 to 3 mg/L, and 3395 (34.9%) with hsCRP OT >3 mg/L. Baseline characteristics according to hsCRP OT are shown in Table 2 . Patients with higher hsCRP OT were more likely to be women, be obese, have diabetes mellitus or diagnosed hypertension, and be current smokers, but less likely to have prior cardiovascular disease. Several baseline lipid parameters were also significantly different across increasing hsCRP groups, including higher levels of LDL-C, total cholesterol (TC), non-HDL cholesterol (HDL-C), triglycerides, TC/HDL-C ratio, and apolipoprotein B, and lower levels of HDL-C.
Bococizumab Treatment Effects on Lipid Levels and hsCRP
When compared with placebo, bococizumab was associated with statistically significant reductions in LDL-C (-60.5%), TC (-37.6%), non-HDL-C (-54.9%), TC/ HDL-C ratio (-41.1%), apolipoprotein B (-56.0%), and triglycerides (-19.9%) as well as an increase in HDL-C (+6.4%) ( Table 3 ; all P<0.001). By contrast, there was no significant effect on hsCRP; mean percentage change was +6.6% (95% confidence interval [CI], -1.0 to 14.1; P=0.09; median change 0.0%) at 14 weeks and +6.7% (95% CI, -9.3% to 16.9%; P=0.57; median change 0.0%) at 52 weeks (n=3267). Percentage changes in lipid fractions were slightly lower in magnitude in higher hsCRP OT groups (Figure 1 ). Nonetheless, even among those with hsCRP >3 mg/L, the median LDL-C OT at 14 weeks was 41.7 (interquartile range, 25.9-67.0) mg/L. Bococizumab treatment effects by hsCRP OT were similar 
Event Rates According to hsCRP OT and LDL-C OT
Overall, a monotonic increase in adjusted event probabilities for the primary end point was observed with increasing hsCRP OT levels ( Figure 2 ). Event rates in hsCRP OT groups were 1.96, 2.50, and 3.59 per 100 person-years for hsCRP <1, 1 to 2, and >3 mg/L, respectively (Table 4). In multivariable models that adjusted for age and sex (model 1), the corresponding HRs for CVD were 1.0 (reference), 1.23 (95% CI, 0.86-1.75), and 1.79 (95% CI, 1.28-2.50; P-trend<0.001). In models additionally adjusting for traditional cardiovascular risk factors and baseline intensity of statin therapy (model 2), the HR comparing highest to lowest hsCRP OT category (>3 versus <1 mg/L) was 1.67 (95% CI, 1.18-2.37; P=0.004).
Further adjustment for LDL-C OT minimally attenuated this risk (model 3, Table 4 , and Figure 3 , left); adjusted HRs were 1.0 (reference), 1.16 (95% CI, 0.81-1.66), and 1.62 (95% CI, 1.14-2.30; P-trend=0.001).
Adjustments made for other potential confounding or mediating factors had minimal impact on these results. In models adjusting for on-treatment TC/HDL-C ratio (model 3 plus TC/HDL-C), adjusted HRs were 1.0 (reference), 1.13, and 1.58 (P-trend=0.002). In models adjusting for prior history of CVD (including peripheral vascular disease), adjusted HRs (model 3 plus prior CVD) were 1.0 (reference), 1.18, and 1.62 (P-trend=0.001). When adjusted for prior history of chronic kidney disease, HRs (model 3 plus prior chronic kidney disease) were 1.0 (reference), 1.16, and 1.60 (P-trend=0.001).
We found similar hazard ratios when analyses were restricted to the placebo group; adjusted HRs (model 3) were 1.0 (reference), 1.11, and 1.72 (P-trend<0.001) according to hsCRP values at 14 week categorized as <1, 1 to 3, and >3 mg/L, respectively. When individual components of the composite end point were exam- Table 4) . Similar but nonsignificant trends were noted for stroke and unstable angina requiring urgent coronary revascularization.
In parallel analyses in which patients were categorized according to LDL-C OT (<30, 30-50, >50 mg/dL), the HRs for the primary end point were 1.0 (reference), 0.87 (95% CI, 0.62-1.22), and 1.21 (95% CI, 0.87-1.68), with Ptrend=0. 16 in analyses adjusting for model 3 covariates and hsCRP OT instead of LDL-C OT (Figure 2 , right, and Table  III in 
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for hsCRP OT and ≥40 mg/dL for LDL-C OT were used (Tables  IV and V in the online-only Data Supplement).
DISCUSSION
In this population of 9738 high-risk patients concomitantly treated with statins and PSCK9 inhibition, 47.2% had residual inflammatory risk defined by hsCRP OT level ≥2 mg/L, with 34.9% having values >3 mg/L. Individuals with persistent hsCRP elevation tended to be those with multiple risk factors, including diabetes mellitus, obesity, hypertension, and mixed dyslipidemia, conditions known to correlate with, if not be driven by, a proinflammatory state. PCSK9 inhibition with bococizumab had no effect on hsCRP over time. Despite aggressive reduction of LDL-C, there was a continuous gradient in risk for future cardiovascular events according to hsCRP OT . Compared to those without evidence of subclinical inflammation, those with hsCRP OT >3 mg/L (median LDL-C OT , 41.7 mg/dL) had a 62% increase in risk of future cardiovascular events. Elevated hsCRP was significantly associated with increased rates of nonfatal MI, cardiovascular death, and all-cause mortality.
There is broad consensus that atherosclerosis is a disorder of both lipid accumulation and inflammation. From a clinical perspective, extensive prior work has found hsCRP to be an independent predictor of cardiovascular events in both primary prevention and high-risk secondary prevention settings. Further, among patients with residual inflammatory risk, randomized clinical trials have proven the efficacy of statin therapy in primary prevention 16 and anti-inflammatory therapy in secondary prevention. 10 It has been uncertain, however, whether residual inflammatory risk persists after the extremely aggressive reduction in LDL-C that can be achieved with the combination of statin therapy and PCSK9 inhibition. It is important to note that in an era when ever more specialized therapies in cardiovascular medicine continue to emerge, the call for biomarkers that inform clinicians about risk stratification, drug choice, dose-therapeutic responses and, ultimately, personalized interventions will only be amplified.
In this context, these data have several important implications. First, these data clarify that PCSK9 inhibition has no effect on plasma measures of hsCRP, despite large effects on atherogenic lipids. Second, the current data demonstrate that, despite the interrelationships between LDL oxidation and inflammation, the combination of high-intensity statin therapy and PCSK9 inhibition does not fully address inflammatory mechanisms of atherothrombosis that may be detected by elevated levels of hsCRP. In isolation, our post hoc findings are associative and could still be explained by underlying conditions that promote subclinical inflammation. As such, as we have argued elsewhere, 17 combination therapy with PCSK9 inhibition and anti-inflammatory therapy may provide the optimal method to address residual cardiovascular risk, a hypothesis that requires a prospective 2×2 factorial trial for adequate testing. Although canakinumab is currently the only anti-inflammatory agent proven to reduce cardiovascular events, clinical trials are currently in progress using colchicine and low-dose methotrexate. 18, 19 Novel agents that inhibit the upstream NLRP3 inflammasome and downstream activation of interleukin-6 are also under consideration. It is important to note that our data do not pertain to the setting of acute coronary syndromes, where anti-inflammatory therapies have thus far failed to impart cardiovascular benefit.
The SPIRE cardiovascular outcomes trials were stopped early because of high rates of development of neutralizing antidrug antibodies. 20 Although bococizumab immunogenicity is associated with a less durable LDL reduction, treatment with bococizumab in the longer duration Model 1, age-and sex-adjusted. Model 2, additionally adjusted for baseline smoking, diabetes mellitus, hypertension, body mass index, and baseline statin (moderate-or high-intensity). Model 3, additionally adjusted for on-treatment LDL-C OT (no. missing=76). All models stratified by study (SPIRE-1 or SPIRE-2), region, and LDL-C screening. hsCRP OT indicates on-treatment levels of highsensitivity C-reactive protein; LDL-C OT , on-treatment levels of low-density lipoprotein cholesterol; and ref, reference. *The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death.
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Circulation. 12, 21 and preliminary data from the ODESSY Outcomes trial. 22 Thus, we believe our findings are unlikely to be explained by diminished bococizumab LDL-C-lowering efficacy and likely to apply more broadly to biological agents in this therapeutic class. As in any post hoc analysis, our findings may be susceptible to residual confounding. In particular, patients with persistent inflammatory risk were more likely to have cardiovascular risk factors and higher median on-treatment LDL-C OT . However, our multivariable analyses adjusted for achieved LDL-C levels and showed minimal, if any, attenuation in risk. Furthermore, as shown in CANTOS, which enrolled on the basis of elevated hsCRP, this risk group is likely to benefit from anti-inflammatory therapy. 10 Consistent associations were noted for the individual trial end points of nonfatal MI, cardiovascular mortality, and all-cause mortality. However, it should be noted that the number of events was small. Thus, these findings must be interpreted with caution.
In summary, these contemporary randomized trial data demonstrate that elevated levels of hsCRP OT remain a significant predictor of future cardiovascular risk among patients with stable atherosclerosis concomitantly treated with statins and PCSK9 inhibition. This evidence of residual inflammatory risk despite maximal LDL-C lowering, if replicated in other cohorts, suggests that inflammation modulation may offer additional opportunities for cardiovascular risk reduction. 
